[The treatment of different forms of B and delta hepatitis with interferon preparations].
A study was made of the therapeutic efficacy of human leukocytic interferon (HLI) and leikinferon in the treatment of HBV- and HDV-infection. 21 patients were placed under observation. Of these, 6 presented with lingering hepatitis B (HB), 8 with chronic HB, 1 was a HBsAg carrier, 4 had Grades I-IV, acute hepatic encephalopathy, and 2 acute hepatitis delta. 15 patients received leikinferon, 6 were given HLI for injections. Indications and schemes for the treatment with interferon preparations are provided as are the clinico-biochemical and serological criteria for estimating the efficacy of interferon therapy. In lingering and chronic forms of HB, leikinferon exerts a beneficial effect. It is not costly, thus enabling one to carry out continuous treatment in patients suffering from chronic forms. HLI may be recommended as an effective agent.